Total Payments
$1.2M
2024 Payments
$112,960
Companies
77
Transactions
1,903
Medicare Patients
6,841
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$881,197 (73.5%)
Consulting$160,801 (13.4%)
Travel$120,587 (10.1%)
Food & Beverage$36,306 (3.0%)
Research$521.73 (0.0%)
Education$20.38 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $589,401 | 3 | 49.1% |
| Honoraria | $179,238 | 74 | 14.9% |
| Consulting Fee | $160,801 | 49 | 13.4% |
| Travel and Lodging | $120,587 | 314 | 10.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $96,584 | 46 | 8.1% |
| Food and Beverage | $36,306 | 1,371 | 3.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $15,975 | 4 | 1.3% |
| Unspecified | $521.73 | 18 | 0.0% |
| Education | $20.38 | 24 | 0.0% |
Payments by Type
General
$1.2M
1,885 transactions
Research
$521.73
8 transactions
Ownership
$0
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Axsome Therapeutics, Inc. | $424,949 | 2 | $0 (2023) |
| GRT US Holding, Inc. | $201,384 | 230 | $0 (2022) |
| Curonix LLC | $164,500 | 4 | $0 (2024) |
| Averitas Pharma Inc. | $161,315 | 240 | $0 (2024) |
| Vertos Medical, Inc. | $120,190 | 139 | $0 (2024) |
| Depomed, Inc. | $25,623 | 59 | $0 (2017) |
| Pernix Therapeutics Holdings, Inc. | $22,927 | 59 | $0 (2018) |
| Abbott Laboratories | $14,357 | 237 | $0 (2024) |
| BIOTRONIK NRO, Inc. | $10,543 | 34 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $9,707 | 106 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,960 | 272 | Averitas Pharma Inc. ($83,159) |
| 2023 | $94,863 | 277 | Averitas Pharma Inc. ($78,155) |
| 2022 | $793,219 | 426 | Axsome Therapeutics, Inc. ($424,921) |
| 2021 | $51,864 | 203 | GRT US Holding, Inc. ($28,712) |
| 2020 | $48,152 | 133 | Vertos Medical, Inc. ($44,281) |
| 2019 | $24,713 | 197 | Vertos Medical, Inc. ($19,140) |
| 2018 | $20,408 | 167 | Stimwave Technologies Incorporated ($7,160) |
| 2017 | $53,254 | 228 | Depomed, Inc. ($25,623) |
All Payment Transactions
1,903 individual payment records from CMS Open Payments — Page 1 of 77
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | BIOTRONIK NRO, Inc. | Prospera (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,525.00 | General |
| Category: Not Applicable | ||||||
| 12/20/2024 | BIOTRONIK NRO, Inc. | Prospera (Device) | Travel and Lodging | In-kind items and services | $15.00 | General |
| Category: Not Applicable | ||||||
| 12/18/2024 | Pacira Pharmaceuticals Incorporated | Exparel (Drug), Iovera, Zilretta | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Pain Management | ||||||
| 12/17/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/17/2024 | Electronic Waveform Lab, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.08 | General |
| 12/13/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Neuromodulation | ||||||
| 12/11/2024 | Stryker Corporation | MILD DEVICE KIT (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: INSTRUMENTS | ||||||
| 12/11/2024 | Stryker Corporation | MILD DEVICE KIT (Device) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: INSTRUMENTS | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,222.50 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $237.33 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $116.64 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | BIOTRONIK NRO, Inc. | Prospera (Device) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: Not Applicable | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $31.70 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $14.74 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/10/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | Cash or cash equivalent | $10.49 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/04/2024 | BIOTRONIK NRO, Inc. | Prospera (Device) | Food and Beverage | In-kind items and services | $125.36 | General |
| Category: Not Applicable | ||||||
| 12/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $396.97 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $162.99 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $116.76 | General |
| Category: PAIN MANAGEMENT | ||||||
| 11/22/2024 | BIOTRONIK NRO, Inc. | Prospera (Device) | Food and Beverage | In-kind items and services | $171.00 | General |
| Category: Not Applicable | ||||||
| 11/19/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $13.08 | General |
| Category: Opioid Analgesic | ||||||
| 11/13/2024 | Electronic Waveform Lab, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.36 | General |
| 11/12/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: PAIN MANAGEMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Evoke Study | Saluda Medical Americas, Inc. | $521.73 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,227 | 2,294 | $979,240 | $205,322 |
| 2022 | 24 | 1,739 | 30,696 | $2.1M | $551,064 |
| 2021 | 28 | 1,879 | 5,422 | $1.6M | $544,661 |
| 2020 | 31 | 1,996 | 6,054 | $1.9M | $508,800 |
Total Patients
6,841
Total Services
44,466
Medicare Billing
$1.8M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 442 | 1,196 | $538,650 | $104,761 | 19.4% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Facility | 2023 | 98 | 163 | $81,510 | $17,014 | 20.9% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 62 | 67 | $51,000 | $15,990 | 31.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 102 | 102 | $59,160 | $13,297 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 122 | $39,040 | $8,516 | 21.8% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Facility | 2023 | 45 | 82 | $35,650 | $7,529 | 21.1% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Facility | 2023 | 31 | 33 | $39,270 | $6,604 | 16.8% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Facility | 2023 | 45 | 80 | $20,160 | $4,129 | 20.5% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 60 | 65 | $12,540 | $3,902 | 31.1% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Facility | 2023 | 53 | 85 | $15,300 | $3,644 | 23.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $14,430 | $3,147 | 21.8% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Facility | 2023 | 20 | 34 | $12,580 | $2,738 | 21.8% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Facility | 2023 | 15 | 25 | $10,360 | $2,347 | 22.7% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Facility | 2023 | 31 | 36 | $11,000 | $2,253 | 20.5% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 13 | 13 | $6,110 | $1,995 | 32.7% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Facility | 2023 | 13 | 22 | $8,700 | $1,626 | 18.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2023 | 17 | 34 | $6,880 | $1,483 | 21.6% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 13 | 13 | $4,550 | $1,458 | 32.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 18 | 24 | $5,750 | $1,366 | 23.8% |
| 64491 | Injection of upper or middle spine facet joint using imaging guidance, second level | Facility | 2023 | 15 | 25 | $5,880 | $1,322 | 22.5% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 15 | 36 | $720.00 | $201.49 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 542 | 3,211 | $1.1M | $322,328 | 28.5% |
| J7336 | Capsaicin 8% patch, per square centimeter | Office | 2022 | 12 | 25,760 | $257,600 | $66,035 | 25.6% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 113 | 113 | $74,355 | $27,653 | 37.2% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Facility | 2022 | 110 | 218 | $141,250 | $24,713 | 17.5% |
About Dr. Mark Coleman, MD
Dr. Mark Coleman, MD is a Interventional Pain Medicine healthcare provider based in Pikesville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1821095431.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Coleman, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $112,960 received in 2024. These payments were reported across 1,903 transactions from 77 companies. The most common payment nature is "Acquisitions" ($589,401).
As a Medicare-enrolled provider, Coleman has provided services to 6,841 Medicare beneficiaries, totaling 44,466 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Pain Medicine
- Location Pikesville, MD
- Active Since 06/29/2005
- Last Updated 06/18/2021
- Taxonomy Code 208VP0014X
- Entity Type Individual
- NPI Number 1821095431
Products in Payments
- Qutenza (Drug) $201,384
- StimQ Receiver Stimulator Kit Channel A US w/Receiver (Device) $157,728
- QUTENZA (Drug) $155,798
- mild Device Kit (Device) $120,190
- ZOHYDRO ER (Drug) $22,927
- Nucynta (Drug) $20,538
- Prospera (Device) $10,348
- PROCLAIM (Device) $9,197
- Xtampza ER (Drug) $8,587
- ZTLido (Drug) $8,361
- INTELLIS ADAPTIVESTIM (Device) $6,066
- Gralise (Drug) $5,075
- Proclaim Family of SCS IPGs (Device) $2,219
- MILD DEVICE KIT (Device) $1,772
- Transfasten LSF (Device) $1,297
- HA MINUTEMAN G3-R (Device) $1,152
- INTELLIS (Device) $1,090
- XTAMPZA (Drug) $1,016
- Evoke (Device) $760.77
- DUEXIS (Drug) $696.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.